Dr. Mark N. Stein, MD

Medicare patients and services

Medicare patients, 2024

226

Services billed

955

Patients’ average age

76

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 15 payments worth $11,671 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $3,087,454 in research payments for these studies, mostly to the institutions running them.

• A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody)Combined with JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
  Janssen Research & Development, LLC
• A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
  Amgen Inc.
• Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)
  Exelixis Inc.
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT03972657
• A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer
  Janssen Research & Development, LLC
• A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS…
  E.r. Squibb & Sons, L.l.c.
• A Phase 1 Dose Escalation Study of JNJ75229414 a Chimeric Antigen Receptor T cell CART Therapy Directed Against KLK2 for Metastatic Castration Resistant Prostate Cancer
  Janssen Research & Development, LLC
• A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer
  E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New York

• Ghassan K. Abou-alfa, MD
• Nour Abuhadra
• Melissa Accordino
• David H. Aggen, M.D., PH.D.
• Carol Aghajanian, MD
• Omobolaji O. Akala, MD/PHD
• Duaa H. Al Rawi, MD PHD
• Louis M. Aledort, MD